KT-621, an Oral STAT6 Degrader, Consistently Improves Moderate-to-Severe Atopic Dermatitis Across Body Regions: Phase 1b Results

KT-621, an Oral STAT6 Degrader, Consistently Improves Moderate-to-Severe Atopic Dermatitis Across Body Regions: Phase 1b Results

American Academy of Dermatology (AAD) 2026 Innovation Academy

Jonathan I. Silverberg¹, Jared Gollob², Neil Graham², Kelvin Shi², Anna M. Tallman², Joyoti Dey², Mahta Mortezavi², Sagar Agarwal², Nello Mainolfi²

¹The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

²Kymera Therapeutics, Inc., Watertown, MA, USA